Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease

Systematic review with meta‐analysis: use of 5‐aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease

“…Twenty‐one studies evaluated the association of 5‐ASA with CRC risk, while five studies reported data for dysplasia. Exposure to 5‐ASA was significantly associated with a protective effect against both outcomes (cancer: RR = 0.58, 95% CI: 0.45–0.74, Figure ; dysplasia: RR = 0.54, 95% CI: 0.35–0.84, Figure ) (Table ).…”

Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

“…The evidence to support this indication in CD is limited . Although case‐control cohorts have suggested a possible beneficial role of aminosalicylates as chemoprophylactic agents in patients with colonic inflammation, this has not been supported in large population‐based studies, and has been primarily derived from data in UC, not CD.…”

Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study

“…In UC, aminosalicylates have been promoted as colorectal chemopreventive agents [24,25]. However, the large number of clinical studies on this subject are mainly observational with disparate methodologies and their results are conflicting [10,[26][27][28]. To our knowledge, no documentation for this treatment in PSC-IBD exists, neither in non-transplanted nor in transplanted patients.…”